A Phase 2 interventional study of Chloroprocaine HCl 1% in Short Duration Lower Limb Surgery Via Spinal Anaesthesia, sponsored by Sintetica SA. Completed at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-05-18.
Sponsored by Sintetica SA · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluate the effect of 3 doses of Chloroprocaine HCl 1% (30, 40 and 50 mg) for spinal anaesthesia in adult patients undergoing short duration elective surgery of the lower limb. Patients undergoing elective short-duration lower limb surgery will be randomised into 3 treatment groups (15 patients per group) to receive one of the 3 single doses of Chloroprocaine HCl 1%, i.e. either D1, D2 or D3, via intrathecal injection.
To evaluate the efficacy of the three Chloroprocaine HCl 1% doses (i.e. D1, D2 and D3) in terms of time to complete regression of spinal block (i.e. end of anaesthesia)
Sintetica SA is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
Drug: Chloroprocaine HCl 1%
Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
Drug: Chloroprocaine HCl 1%
Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
Drug: Chloroprocaine HCl 1%
Intrathecal Route
Also known as: Ampres 1%
Time to Regression of Spinal Block
When Bromage score returns to 0 and sensitive perception returns to S1 To evaluate the efficacy of the three Chloroprocaine HCI 1% doses (i.e. 30 mg, 40 mg e 50 mg) in terms of time to complete regression of spinal block (i.e. end of anaesthesia) Bromage Score is comprised between 1 and 4 (1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)
Time frame: Up to 5 hours after regression of two dermatomers
Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)
Time period from spinal injection (time 0 h) to achievement of sensory block The evolution of both sensory and motor blocks, including sensory block metameric level, will be evaluated every 2 min until readiness for surgery, every 5 min until the maximum level is reached (two consecutive observations with the same level of sensory block) and then every 5 min until regression of two dermatomers with respect to the maximum level of sensory block.
Time frame: Up to 40 min after spinal injection
Time to Onset of Motor Block
Time period from spinal injection (time 0 h) to achievement of motor block
Time frame: Up to 40 min after spinal injection
Time to Readiness for Surgery
Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery, i.e. loss of Pinprick sensation and Bromage's score ≥ 2 at the required metameric level ≥ T12
Time frame: Up to 40 min after spinal injection
Time to Regression of Spinal Block
Time frame: Up to 1 h and 40 min after readiness for surgery
Time to Resolution of Sensory Block to S1(Min)
Time period from spinal injection (time 0 h) to the time when sensitive perception has returned to S1
Time frame: Up to 5 h after regression of two dermatomers
Time to Resolution of Motor Block
Time period from spinal injection (time 0 h) to the time when the Bromage score has returned to 0 (Bromage Scale comprises from 1 to 4, where 1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)
Time frame: Up to 5 h after regression of two dermatomers
Time to Unassisted Ambulation
Time period from spinal injection (time 0 h) to the time when the patient can walk unassisted
Time frame: Up to 5 h after regression of two dermatomers
Sensory Block Metameric Level
Metameric level of sensory block assessed from spinal injection (time 0 h) until regression of sensory block to S1
Time frame: Up to 5 h after regression of two dermatomers
Maximum Level of Sensory Block
Maximum metameric level of sensory block (decreased or absent sensation) achieved
Time frame: Up to 1 h and 40 min after readiness for surgery
Time to Maximum Level of Sensory Block
Time period from spinal injection (Tsp; time 0 h) to the time when the maximum metameric level of sensory block is achieved (consider the time of the first of the two consecutive observations with the same level of sensory block)
Time frame: Up to 1 h and 40 min after readiness for surgery
Time to Regression of Two Dermatomers With Respect to the Maximum Level of Sensory Block
Time period from spinal injection (time 0 h) to the time when the sensory block decrease of two dermatomers with respect to the maximum level of sensory block
Time frame: Up to 5 h after regression of two dermatomers
Time to Eligibility for Home Discharge
Time period from spinal injection (time 0 h) to the time when the criteria from discharge are met, even if according to the hospital procedures the patient is discharged at a later time
Time frame: Expected up to 24 hrs post surgery
Time to First Spontaneous Urine Voiding
Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted
Time frame: Expected up to 24 hrs post surgery
Time to First Post-operative Analgesia
Time from spinal injection (time 0 h) to first post-operative analgesia
Time frame: Expected up to 24 hrs post surgery
Time to Administration of Rescue Anaesthesia or Rescue Analgesia
Time frame: Expected up to 24 hrs post surgery
Concentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma
Time frame: at pre-dose, 5, 10, 30 and 60 min after spinal puncture
Excretion of 2-chloro-4-aminobenzoic Acid (CABA) in Urine
Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted
Time frame: at the time of first urine voiding post surgery
Treatment-emergent Adverse Events (TEAEs)
All AEs occurring or worsening after the dose of IMP
Time frame: Up to Day 6 +/- 1 after spinal puncture
Transient Neurological Symptoms (TNS)
Time frame: Up to Day 6 +/- 1 after spinal puncture
Pain Assessment at the Site of Injection and at the Site of Surgery
Number of patients with pain at the site of injection and at the site of surgery
Time frame: Up to Day 6 +/- 1 after spinal puncture
Heart Rate
The following normal ranges Heart Rate parameters will be used: 50-90 beats/min
Time frame: Expected up to 24 hrs post surgery
Blood Pressure
The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used: Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg
Time frame: Expected up to 24 hrs post surgery
SpO2
The following normal ranges SpO2 parameters will be used: Peripheral Oxygen Saturation: ≥ 95%
Time frame: Expected up to 24 hrs post surgery
| Milestone | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Started | 15 | 15 | 15 |
| Completed | 15 | 15 | 15 |
| Not completed | 0 | 0 | 0 |
When Bromage score returns to 0 and sensitive perception returns to S1 To evaluate the efficacy of the three Chloroprocaine HCI 1% doses (i.e. 30 mg, 40 mg e 50 mg) in terms of time to complete regression of spinal block (i.e. end of anaesthesia) Bromage Score is comprised between 1 and 4 (1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)
| minutes | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Time to Regression of Spinal Block | 40.8 ± 12.1 | 39.4 ± 12.5 | 41.5 ± 13.9 |
Time period from spinal injection (time 0 h) to achievement of sensory block The evolution of both sensory and motor blocks, including sensory block metameric level, will be evaluated every 2 min until readiness for surgery, every 5 min until the maximum level is reached (two consecutive observations with the same level of sensory block) and then every 5 min until regression of two dermatomers with respect to the maximum level of sensory block.
| minutes | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Time to Onset of Sensory Block (Corresponding to Readiness for Surgery) | 5.4 ± 3 | 6.6 ± 3.4 | 4.8 ± 2 |
Time period from spinal injection (time 0 h) to achievement of motor block
| minutes | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Time to Onset of Motor Block | 6.3 ± 3.2 | 6 ± 3.3 | 4.4 ± 2.3 |
Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery, i.e. loss of Pinprick sensation and Bromage's score ≥ 2 at the required metameric level ≥ T12
| minutes | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Time to Readiness for Surgery | 8 ± 4.1 | 7.9 ± 4.7 | 5.3 ± 2 |
| hours | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Time to Regression of Spinal Block | 1.761 ± 0.348 | 2.127 ± 0.457 | 2.229 ± 0.379 |
Time period from spinal injection (time 0 h) to the time when sensitive perception has returned to S1
| hours | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Time to Resolution of Sensory Block to S1(Min) | 1.761 ± 0.348 | 2.127 ± 0.457 | 2.195 ± 0.386 |
Time period from spinal injection (time 0 h) to the time when the Bromage score has returned to 0 (Bromage Scale comprises from 1 to 4, where 1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)
| hours | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Time to Resolution of Motor Block | 2.662 ± 0.789 | 3.361 ± 1.120 | 3.213 ± 0.856 |
Time period from spinal injection (time 0 h) to the time when the patient can walk unassisted
| hours | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Time to Unassisted Ambulation | 2.662 ± 0.789 | 3.361 ± 1.120 | 3.213 ± 0.856 |
Metameric level of sensory block assessed from spinal injection (time 0 h) until regression of sensory block to S1
| participants | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| T2 | 0 | 2 | 2 |
| T3 | 1 | 0 | 1 |
| T4 | 3 | 2 | 1 |
| T6 | 0 | 1 | 4 |
| T7 | 1 | 0 | 1 |
| T8 | 3 | 3 | 2 |
| T10 | 3 | 1 | 3 |
| T12 | 3 | 5 | 1 |
| L1 | 1 | 1 | 0 |
Maximum metameric level of sensory block (decreased or absent sensation) achieved
| participants | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| T2 | 0 | 2 | 2 |
| T3 | 1 | 0 | 1 |
| T4 | 3 | 2 | 1 |
| T6 | 0 | 1 | 4 |
| T7 | 1 | 0 | 1 |
| T8 | 3 | 3 | 2 |
| T10 | 3 | 1 | 3 |
| T12 | 3 | 5 | 1 |
| L1 | 1 | 1 | 0 |
Time period from spinal injection (Tsp; time 0 h) to the time when the maximum metameric level of sensory block is achieved (consider the time of the first of the two consecutive observations with the same level of sensory block)
| minutes | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Time to Maximum Level of Sensory Block | 0.224 ± 0.14 | 0.235 ± 0.077 | 0.234 ± 0.098 |
Time period from spinal injection (time 0 h) to the time when the sensory block decrease of two dermatomers with respect to the maximum level of sensory block
| hours | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Time to Regression of Two Dermatomers With Respect to the Maximum Level of Sensory Block | 0.687 ± 0.361 | 0.851 ± 0.468 | 0.695 ± 0.290 |
Time period from spinal injection (time 0 h) to the time when the criteria from discharge are met, even if according to the hospital procedures the patient is discharged at a later time
| hours | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Time to Eligibility for Home Discharge | 3.021 ± 1.012 | 3.545 ± 1.281 | 3.530 ± 0.887 |
Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted
| hours | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Time to First Spontaneous Urine Voiding | 2.530 ± 0.761 | 3.361 ± 1.120 | 3.067 ± 0.755 |
Time from spinal injection (time 0 h) to first post-operative analgesia
| hours | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Time to First Post-operative Analgesia | 8.186 ± 10.815 | 2.928 ± 1.228 | 2.988 ± 1.167 |
| hours | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Time to Administration of Rescue Anaesthesia or Rescue Analgesia | 0.717 ± 0.397 | 0.315 ± 0.049 | 0 ± 0 |
| minutes | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| 5 minutes post-dose | 16.127 ± 20.108 | 20.411 ± 23.037 | 24.887 ± 20.340 |
| 10 minutes post-dose | 41.440 ± 31.778 | 38.851 ± 25.492 | 75.833 ± 67.635 |
| 30 minutes post-dose | 57.459 ± 43.773 | 67.180 ± 36.899 | 97.647 ± 61.704 |
| 60 minutes post-dose | 47.020 ± 41.381 | 53.093 ± 31.803 | 78.380 ± 48.403 |
Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted
| ng/mL | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Excretion of 2-chloro-4-aminobenzoic Acid (CABA) in Urine | 1217.7 ± 627.8 | 1827.9 ± 904.1 | 2103.5 ± 1537.5 |
All AEs occurring or worsening after the dose of IMP
| participants | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Procedural pain | 14 | 13 | 13 |
| Injection site pain | 2 | 3 | 3 |
| nausea | 0 | 1 | 1 |
| diarrhea | 0 | 1 | 0 |
| vomiting | 0 | 1 | 0 |
| bradycardia | 0 | 1 | 0 |
| participants | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| day 2 | 0 | 0 | 0 |
| day 7 | 0 | 0 | 0 |
Number of patients with pain at the site of injection and at the site of surgery
| participants | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Immediately after regression of spinal block | 0 | 0 | 0 |
| discharge | 0 | 0 | 0 |
| day 2 | 14 | 15 | 15 |
| day 7 | 15 | 15 | 15 |
The following normal ranges Heart Rate parameters will be used: 50-90 beats/min
| beats/min | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| screening | 62.2 ± 8.5 | 67.5 ± 11.4 | 70.7 ± 8.6 |
| baseline | 63.1 ± 9.4 | 71 ± 14 | 71.7 ± 9.2 |
| discharge | 64.9 ± 7 | 66.9 ± 10 | 67 ± 8 |
The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used: Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg
| mmHg | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Systolic Blood Pressure screening | 120 ± 12.9 | 126 ± 21.74 | 121.6 ± 9.1 |
| Systolic Blood Pressure baseline | 116.9 ± 10.5 | 127.9 ± 19.7 | 125.5 ± 14.1 |
| Systolic Blood Pressure discharge | 116.9 ± 10.9 | 124.7 ± 14.7 | 121.7 ± 8.9 |
| Diastolic Blood Pressure screening | 81.5 ± 12.1 | 78.9 ± 11.9 | 80.5 ± 9.9 |
| Diastolic Blood Pressure baseline | 74.5 ± 10.3 | 79.8 ± 10.9 | 79.1 ± 13.3 |
| Diastolic Blood Pressure discharge | 75.5 ± 12.2 | 79 ± 8.1 | 82 ± 9.5 |
The following normal ranges SpO2 parameters will be used: Peripheral Oxygen Saturation: ≥ 95%
| percentage | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| screening | 99.7 ± 0.96 | 99.13 ± 1.25 | 98.53 ± 1.36 |
| baseline | 99.4 ± 0.91 | 99.13 ± 0.83 | 98.53 ± 1.51 |
| discharge | 99.33 ± 0.72 | 99.33 ± 0.90 | 99 ± 1.07 |
Collected over 7 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3 mL Chloroprocaine HCl 1% | — | 0/15 (0%) | 15/15 (100%) |
| 4 mL Chloroprocaine HCl 1% | — | 0/15 (0%) | 13/15 (86.7%) |
| 5 mL Chloroprocaine HCl 1% | — | 0/15 (0%) | 13/15 (86.7%) |
| Event | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% |
|---|---|---|---|
| Procedural painInjury, poisoning and procedural complications | 14/15 | 13/15 | 13/15 |
| injection site painGeneral disorders | 2/15 | 3/15 | 3/15 |
| nauseaGastrointestinal disorders | 0/15 | 1/15 | 1/15 |
| diarrhoaeGastrointestinal disorders | 0/15 | 1/15 | 0/15 |
| vomitingGastrointestinal disorders | 0/15 | 1/15 | 0/15 |
| bradycardiaCardiac disorders | 0/15 | 1/15 | 0/15 |
| Age, Categorical(Participants) | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% | Total |
|---|---|---|---|---|
| <=18 years | 0.0 | 0.0 | 0.0 | 0 |
| Between 18 and 65 years | 15 | 15 | 15 | 45 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% | Total |
|---|---|---|---|---|
| Mean | 41.0 ± 11.7 | 39.4 ± 12.5 | 41.5 ± 13.9 | 40.6 ± 12.5 |
| Sex: Female, Male(Participants) | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% | Total |
|---|---|---|---|---|
| Female | 6 | 6 | 6 | 18 |
| Male | 9 | 9 | 9 | 27 |
| Region of Enrollment(participants) | 3 mL Chloroprocaine HCl 1% | 4 mL Chloroprocaine HCl 1% | 5 mL Chloroprocaine HCl 1% | Total |
|---|---|---|---|---|
| Italy | 15 | 15 | 15 | 45 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jun 2015, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2021, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chloroprocaine
Sintetica SA